Erlotinib used for the treatment of advanced brain metastases from lung adenocarcinomas after arterial infusion chemotherapy: A clinical analysis

Chuntao Ma, Zhi Guo
{"title":"Erlotinib used for the treatment of advanced brain metastases from lung adenocarcinomas after arterial infusion chemotherapy: A clinical analysis","authors":"Chuntao Ma, Zhi Guo","doi":"10.3969/J.ISSN.1008-794X.2012.08.007","DOIUrl":null,"url":null,"abstract":"Objective To explore the clinical efficacy and the adverse effects of erlotinib,used as a 2nd-line treatment,in treating lung adenocarcinoma complicated by brain metastases after the failure of arterial infusion chemotherapy.Methods During the period from November 2008 to January 2011,a total of 20 cases with lung adenocarcinoma complicated by brain metastases received arterial infusion chemotherapy. This procedure was performed once every 4 weeks until the intracranial lesions became worse or intolerable toxicity emerged.Then erlotinib was employed as a 2nd-line treatment in all the patients.The dose of erlotinib was 150 mg/day,and the treatment was kept on till the diseases deteriorated or intolerable adverse effects occurred.The remission rate,progression free survival time,overall survival time and the adverse effects of erlotinib were evaluated.Results All the 20 patients received arterial infusion chemotherapy for at least 2 times,the median treatment times was 3 times.For the 20 cases receiving erlotinib treatment,the overall response rate(CR + PR) was 75%(15/20) and the disease control rate(CR + PR + SD) was 90%(18/20). The median progression free survival time was 9 months with the 95%CI being(7.65 - 10.35) months.The Overall median survival time was 15 months and the 95%CI was(11.48 - 18.53) months.The 6-month survival rate and one-year survival rate were 90%and 75%respectively.The most common adverse effects of erlotinib were skin rash(90%,18/20) and diarrhea(75%,15/20).Most adverse effects were of gradeⅠ-Ⅱ,and only 10%(2/20) of patients got adverse effects of≥3grade.Conclusion As a 2nd-line treatment for lung adenocarcinoma with brain metastases,erlotinib is very effective and tolerable.Therefore,erlotinib can be employed as a therapeutic option for the patients who has failed to respond to the arterial infusion chemotherapy.)","PeriodicalId":52558,"journal":{"name":"Journal of Interventional Radiology","volume":"21 1","pages":"641-644"},"PeriodicalIF":0.0000,"publicationDate":"2012-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Interventional Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3969/J.ISSN.1008-794X.2012.08.007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

Abstract

Objective To explore the clinical efficacy and the adverse effects of erlotinib,used as a 2nd-line treatment,in treating lung adenocarcinoma complicated by brain metastases after the failure of arterial infusion chemotherapy.Methods During the period from November 2008 to January 2011,a total of 20 cases with lung adenocarcinoma complicated by brain metastases received arterial infusion chemotherapy. This procedure was performed once every 4 weeks until the intracranial lesions became worse or intolerable toxicity emerged.Then erlotinib was employed as a 2nd-line treatment in all the patients.The dose of erlotinib was 150 mg/day,and the treatment was kept on till the diseases deteriorated or intolerable adverse effects occurred.The remission rate,progression free survival time,overall survival time and the adverse effects of erlotinib were evaluated.Results All the 20 patients received arterial infusion chemotherapy for at least 2 times,the median treatment times was 3 times.For the 20 cases receiving erlotinib treatment,the overall response rate(CR + PR) was 75%(15/20) and the disease control rate(CR + PR + SD) was 90%(18/20). The median progression free survival time was 9 months with the 95%CI being(7.65 - 10.35) months.The Overall median survival time was 15 months and the 95%CI was(11.48 - 18.53) months.The 6-month survival rate and one-year survival rate were 90%and 75%respectively.The most common adverse effects of erlotinib were skin rash(90%,18/20) and diarrhea(75%,15/20).Most adverse effects were of gradeⅠ-Ⅱ,and only 10%(2/20) of patients got adverse effects of≥3grade.Conclusion As a 2nd-line treatment for lung adenocarcinoma with brain metastases,erlotinib is very effective and tolerable.Therefore,erlotinib can be employed as a therapeutic option for the patients who has failed to respond to the arterial infusion chemotherapy.)
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
厄洛替尼用于动脉输注化疗后晚期肺腺癌脑转移的治疗:临床分析
目的探讨厄洛替尼作为二线治疗肺动脉输注化疗失败后肺腺癌合并脑转移的临床疗效及不良反应。方法2008年11月至2011年1月对20例肺腺癌合并脑转移患者行动脉输注化疗。该手术每4周进行一次,直到颅内病变恶化或出现难以忍受的毒性。然后厄洛替尼作为二线治疗在所有的患者。厄洛替尼剂量为150mg /d,持续治疗至病情恶化或出现难以忍受的不良反应。评估缓解率、无进展生存时间、总生存时间和厄洛替尼的不良反应。结果20例患者均接受了至少2次动脉灌注化疗,中位治疗次数为3次。接受埃洛替尼治疗的20例患者,总有效率(CR + PR)为75%(15/20),疾病控制率(CR + PR + SD)为90%(18/20)。中位无进展生存期为9个月,95%CI为(7.65 ~ 10.35)个月。总中位生存时间为15个月,95%CI为(11.48 ~ 18.53)个月。6个月生存率为90%,1年生存率为75%。厄洛替尼最常见的不良反应是皮疹(90%,18/20)和腹泻(75%,15/20)。大多数不良反应为Ⅰ-Ⅱ级,只有10%(2/20)的患者出现≥3级的不良反应。结论厄洛替尼作为肺腺癌脑转移的二线治疗药物,具有良好的疗效和耐受性。因此,厄洛替尼可作为动脉输注化疗无效的患者的治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Interventional Radiology
Journal of Interventional Radiology Medicine-Radiology, Nuclear Medicine and Imaging
自引率
0.00%
发文量
0
期刊最新文献
The clinical application of DSA and Xper-CT in guiding lung tumor radiofrequency ablation procedure CT-guided radioactive 125I seeds implantation as a salvage therapy for adrenal metastases: Evaluation of short-term effect in 11 cases The effect of high mobility group protein B1 on cryoimmunologic reaction in hormone-refractory prostate cancer: An experimental study in rats CT-guided radioactive seeds 125I implantation used as salvage therapy for malignant pelvic tumors: evaluation of short-term effects The effect of regulatory T cells level in peripheral blood on the prognosis in HCC patients after TACE
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1